Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug

  • Stifel has upgraded BioMarin Pharmaceutical Inc's BMRN to Buy from Hold with a price target of $96, up from $86. 
  • After the stock's "significant underperformance" since August 2020, analyst Paul Matteis is expecting a turnaround with potential Vosoritide FDA approval and a "strong launch after that." 
  • Related Content: Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval.
  • Matteis is optimistic about the approval of Vosoritide even though its "regulatory history is a little scary." 
  • After re-reading the panel transcript and speaking with key opinion leaders, he thinks Vosoritide will more likely than not be approved. 
  • If approved, BioMarin shares will initially go up but continue to grind higher into the launch, Matteis tells investors.
  • Price Action: BMRN shares are up 4.30% at $80 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasNewsUpgradesHealth CarePrice TargetFDAAnalyst RatingsMoversTrading IdeasGeneralBriefsdwarfism
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!